# AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

> **NCT00122343** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 45 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** ridaforolimus

## Key facts

- **NCT ID:** NCT00122343
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2015-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00122343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00122343, "AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT00122343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*